NCT05495464 2026-05-20A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell LymphomaM.D. Anderson Cancer CenterPhase EARLY_PHASE1 Active not recruiting22 enrolled